Applied Molecular Transport to Present at Canaccord Genuity’s 41st Annual Growth Conference
Applied Molecular Transport (Nasdaq: AMTI) announced that CEO Tahir Mahmood will participate in a fireside chat at Canaccord Genuity’s 41st Annual Growth Conference on August 11, 2021, at 2:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Applied Molecular Transport (Nasdaq: AMTI) announced that CEO Tahir Mahmood will participate in a fireside chat at Canaccord Genuity’s 41st Annual Growth Conference on August 11, 2021, at 2:30 p.m. ET. A live webcast will be available on the company’s website, with an archived replay accessible for 30 days post-event.
AMT is a clinical-stage biopharmaceutical firm focused on developing oral biologic product candidates for autoimmune and inflammatory diseases using its proprietary technology platform.
Details
News Market Reaction – AMTI
The recorded move for AMTI in the trading session of this news was +7.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuity’s 41st Annual Growth Conference on Wednesday, August 11, 2021 at 2:30 p.m. ET.
A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelial (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.